IBM Working to Stomp Out “Superbugs”

There are other persistent, grave health crises brewing besides the ongoing COVID-19 pandemic: Antibiotic resistance is one, and the troubling trend is that it’s on the rise, leading to an increase in so-called ‘superbugs’ that are difficult to treat.

IBM Research, working in partnership with Singapore’s Institute of Bioengineering and Nanotechnology, has developed a synthetic macromolecule polymer that can potentially be used to significantly increase the effectiveness of existing antibiotics, rendering them able to fight off emerging superbugs.

In a new paper published in academic journal Advanced Science, the IBM researchers detail their work in creating a polymer that can be combined with course of antibiotics that are used to treat non-resistant strains of infections, in does equal or even lower to those that are found to be effective in treating the varieties of the infections that lack the ability to overcome antibiotics.

The macromolecule works by essentially hitching itself to the enzymes that bacteria modify when they are treated using antibiotics, but not completely eliminated.

[#1 Penny Stock: This Breakthrough Could End the Biggest Killer In The History of Man]

That’s a big reason why you’re always told to take the entire course of an antibiotic when it’s prescribed: If it isn’t completely wiped out, it can rebound and develop resistance to the treatment used when it comes back.

The IBM polymer basically shorts out the protective measures developed by the bacteria when to counter the effects of the antibiotic, returning (or potentially even slightly improving) their efficacy.

This is still relatively early research that’s been done in the highly controlled environment of the lab, and would require a lot more development and testing, including proper clinical trials involving human patients before it actually becomes anything to be used in the real world.

But these lab-based results provide a very promising basis upon which to build that work, having shown demonstrated efficacy with real multidrug-resistant bacterial infections.

[Special: Announcement August 7th Could Trigger a Tsunami of New Wealth Across The Nation]

Read more from Darrell Etherington at TechCrunch.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Write This Stock Ticker Down Right Now

Enter your email below to see the stock name and ticker on the next page.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

#1 A.I. Stock Currently Trading For $6

Gain immediate access to this revolutionary $6 A.I. stock that is set to disrupt a $15 Trillion Market soar 75X.
Enter your email address to receive the name and ticker symbol for free.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

5 Stocks To Buy In 2023

“Project X” could revolutionize a $23 Trillion industry, and potentially be 1,000x bigger than EV’s. 
Enter your email address to receive the companies names and ticker symbols for free.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Write This Stock Ticker Down Right Now

Enter your email address to see the name and ticker on the next page.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

How to Collect "Amazon Royalty" Payouts Before the Deadline

Thanks to a little-known IRS loophole, regular Americans can collect up to $28,544 (or more) in payouts from what is called “Amazon’s secret royalty program”…
Enter your email address to access all the details.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Project An-E

Breakthrough A.I. Just Predicted What the Stock Prices of Tesla, Nvidia, and Apple Will Be 30 Days from Now…
Enter your email address for immediate access.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Elon Musk's "Project Omega"

It could soon mint new millionaires, while plunging millions of unprepared Americans into poverty. Get the stocks at the center of it all.
Enter your email address to receive the names and ticker symbols.


By submitting your email address, you give Breakthrough Investors permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works